la Crosse encephalitis

Summary

la Crosse encephalitis (MONDO:0019378) is a disease. A subtype of mosquito-borne viral encephalitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 100 000 (Canada) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	1.91	Canada	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	la Crosse encephalitis
Mondo ID	MONDO:0019378
MeSH	D004670
Orphanet	83483
DOID	DOID:0050118
ICD-11	1501615629
SNOMED CT	61094002
UMLS	C0276379
MedGen	547309
GARD	0010925
MedDRA	10014584
Is cancer (heuristic)	no

Also known as: Californian encephalitis · La Crosse virus caused infectious encephalitis · La Crosse virus infectious encephalitis

Disease family

This is a subtype of mosquito-borne viral encephalitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › encephalomyelitis › encephalitis › infectious encephalitis › viral encephalitis › mosquito-borne viral encephalitis › la Crosse encephalitis

Related subtypes (4): st. Louis encephalitis, Japanese encephalitis, West-Nile encephalitis, western equine encephalitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.